NDC product
KYMRIAH
NDC 0078-0958 · Novartis Pharmaceuticals Corporation
Key facts
| Product NDC | 0078-0958 |
|---|---|
| Proprietary name | KYMRIAH |
| Nonproprietary name | tisagenlecleucel |
| Substances | TISAGENLECLEUCEL |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAVENOUS |
| Labeler | Novartis Pharmaceuticals Corporation |
| Product type | CELLULAR THERAPY |
| Marketing category | BLA |
| Application number | BLA125646 |
| Pharmacologic classes | CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes and 3 more |
| Marketing start | May 1, 2018 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: